Federal Judge Restores Funding for Gateway Rail Tunnel Project 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Google Halts UK YouTube TV Measurement Service After Legal Action 
NASA and Roscosmos Chiefs Meet in Florida to Discuss Moon and ISS Cooperation 
Asian Markets Surge as Japan Election, Fed Rate Cut Bets, and Tech Rally Lift Global Sentiment 
NASA Astronauts Wilmore and Williams Recover After Boeing Starliner Delay 
Blue Origin’s New Glenn Achieves Breakthrough Success With First NASA Mission 
TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Trump Lifts 25% Tariff on Indian Goods in Strategic U.S.–India Trade and Energy Deal 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
The Seoul Central District Court had ruled that Medytox's patents for botulinum toxin (botox) strains and manufacturing process were stolen by Daewoong Pharmaceutical in developing Nabota.
Thus, the court prohibited Daewoong from manufacturing and selling its botox products, ordering that those that have already been produced should be discarded.
It also ordered Daewoong to pay 40 billion won in damages to Medytox, the first Korean company to succeed in mass-producing botox strains.
Medytox sued Daewoong in 2017, accusing it of stealing its botox strain and manufacturing process.
Daewoong claimed that it found its botox strain in a barn in Gyeonggi Province.
Medytox vowed to continue to protect its patent, while Daewoong said it would appeal the ruling.
The US International Trade Commission (USITC) had earlier ruled in favor of Medytox in December 2020 and ordered a 21-month import ban on Daewoong's products into the US. Daewoong also agreed to pay royalties to Medytox to settle the dispute shortly after the USITC decision.
